Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac
Condition: Healthy Interventions: Biological: GamTBvac vaccine; Biological: placebo Sponsors: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation; contract research organization Cromos Pharma Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Clinical Trials | Epidemiology | Microbiology | Pharmaceuticals | Research | Russia Health | Tuberculosis | Tuberculosis (BCG) Vaccine | Vaccines